0000000000217200

AUTHOR

Michel Bouvier

showing 3 related works from this author

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymph…

1996

International audience; Abstract: The objective was to evaluate the expression of the multidrug resistance P-glycoprotein (P-gp) in peripheral blood lymphocytes (PBL) of patients with rheumatoid arthritis (RA). PBL from 68 RA patients and 44 controls were evaluated. RA patients had a mean disease duration of 10.7 yr, with a mean number of past resistances to DMARDs of 0.82, and were treated with NSAIDs (n = 34), DMARDs (n = 25) and prednisolone (n = 40). Fluorescence flow cytometry was used to assess P-gp membrane expression on PBL. In the RA group, the percentage of PBL expressing P-gp was higher in patients treated with prednisolone than in other patients [mean +/- S.D.: 10.7 +/- 15.8% vs…

Malerheumatoid arthritismedicine.drug_classmedicine.medical_treatmentLymphocytePrednisolone[INFO.INFO-IM] Computer Science [cs]/Medical ImagingDrug resistanceArthritis Rheumatoidresistance03 medical and health sciences0302 clinical medicineRheumatologyImmunopathologyMDRmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Lymphocytes030304 developmental biologyAgedAutoimmune disease0303 health sciencesChemotherapytreatmentglucocorticoids[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryAnti-Inflammatory Agents Non-SteroidaldrugMiddle Agedmedicine.diseaseDrug Resistance Multiple3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisAntirheumatic AgentsImmunologyMultivariate AnalysisPrednisoloneCorticosteroidRegression AnalysisFemalebusinessmedicine.drug
researchProduct

Agonist‐induced desensitisation of β 3 ‐adrenoceptors: Where, when, and how?

2019

β3 -Adrenoceptor agonists have proven useful in the treatment of overactive bladder syndrome, but it is not known whether their efficacy during chronic administration may be limited by receptor-induced desensitisation. Whereas the β2 -adrenoceptor has phosphorylation sites that are important for desensitisation, the β3 -adrenoceptor lacks these; therefore, it had been assumed that β3 -adrenoceptors are largely resistant to agonist-induced desensitisation. While all direct comparative studies demonstrate that β3 -adrenoceptors are less susceptible to desensitisation than β2 -adrenoceptors, desensitisation of β3 -adrenoceptors has been observed in many models and treatment settings. Chimeric …

0301 basic medicinePharmacologyAgonistMessenger RNAmedicine.medical_specialtyCell typePhosphorylation sitesAdrenergic receptormedicine.drug_classbusiness.industryChinese hamster ovary cellTransfection03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyInternal medicinemedicinebusinessReceptor030217 neurology & neurosurgeryBritish Journal of Pharmacology
researchProduct

Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

2019

Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC-IUPHAR [92]) are activated by the endogenous cyclic nonapeptides vasopressin and oxytocin. These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin). Vasopressin and oxytocin differ at only 2 amino acids (positions 3 and 8). There are metabolites of these neuropeptides that may be biologically active [67].

endocrine systemVasopressinChemistryNeurophysin INeuropeptideNeurophysinsPharmacologyOxytocin receptorOxytocinNeurophysin IImedicineReceptorhormones hormone substitutes and hormone antagonistsmedicine.drugIUPHAR/BPS Guide to Pharmacology CITE
researchProduct